Trial Profile
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2022
Price :
$35
*
At a glance
- Drugs Mirvetuximab soravtansine (Primary) ; Doxorubicin liposomal; Gemcitabine; Paclitaxel; Topotecan
- Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms FORWARD I
- Sponsors ImmunoGen
- 28 Oct 2022 According to an ImmunoGen media release, retrospective pooled analysis from Phase 1 IMGN853-0401 trial, the Phase 3 FORWARD I trial, and the Phase 3 SORAYA trials were presented at the 23rd Congress of the European Society of Gynaecological Oncology (ESGO).
- 28 Oct 2022 Retrospective pooled analysis from Phase 1 IMGN853-0401 trial, the Phase 3 FORWARD I trial, and the Phase 3 SORAYA trials are presented in an ImmunoGen media release.
- 13 Sep 2022 Results of Population pharmacokinetic (PK) analysis Analysis from 3 studies(NCT01609556, NCT02631876, NCT04296890) of mirvetuximab soravtansine (MIRV) in patients with folate receptor (FRalpha)-positive cancer presented at the 47th European Society for Medical Oncology Congress